Read by QxMD icon Read

Psychosis alzheimer

Tomoyuki Nagata, Shinichiro Nakajima, Shunichiro Shinagawa, Eric Plitman, Ariel Graff-Guerrero, Masaru Mimura, Kazuhiko Nakayama
OBJECTIVE: This study sought to determine psychosocial and clinico-demographic factors related to each symptomatic cluster (i.e., aggressiveness, psychosis, apathy/eating problems, and emotion/disinhibition) of neuropsychiatric symptoms (NPSs) in patients with Alzheimer's disease (AD) needing interventional treatment against their agitation or psychotic symptoms. These clusters were classified from 12 Neuropsychiatric Inventory (NPI) subscores in our previous study using the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) dataset...
October 7, 2016: International Journal of Geriatric Psychiatry
Julia Kim, Tom A Schweizer, Corinne E Fischer, David G Munoz
BACKGROUND: The pathophysiology behind psychosis in patients with Alzheimer's disease (AD) remains unknown. Vascular risk factors have been recognized as an important modifier of the clinical presentation of AD. OBJECTIVE: The purpose of our study is to investigate the mechanism through which vascular risk factors mediate psychosis and whether or not it involves cerebrovascular lesions. METHODS: Data was provided by the National Alzheimer's Coordinating Centre...
September 21, 2016: Journal of Alzheimer's Disease: JAD
Adrian Wong, Alexander Y L Lau, Jie Yang, Zhaolu Wang, Wenyan Liu, Bonnie Y K Lam, Lisa Au, Lin Shi, Defeng Wang, Winnie C W Chu, Yun-Yun Xiong, Eugene S K Lo, Lorraine S N Law, Thomas W H Leung, Linda C W Lam, Anne Y Y Chan, Yannie O Y Soo, Eric Y L Leung, Lawrence K S Wong, Vincent C T Mok
BACKGROUND: The objectives of this study are 1) to examine the frequencies of neuropsychiatric symptom clusters in patients with stroke or transient ischemic attack (TIA) by cognitive level and stroke subtype; and 2) to evaluate effect of demographic, clinical, and neuroimaging measures of chronic brain changes and amyloid upon neuropsychiatric symptom clusters. METHODS: Hospital-based, cross-sectional study. 518 patients were administered the Neuropsychiatric Inventory (NPI) 3-6 months post index admission...
2016: PloS One
Natasha L Lethbridge, Paul L Chazot
Dementia with Lewy bodies (DLB) is a serious age-dependent human neurodegenerative disease, with multiple debilitating symptoms, including dementia, psychosis and significant motor deficits, but with little or no effective treatments. This comparative ligand autoradiographical study has quantified histamine H3 receptors (H3R) in a series of major cortical and basal ganglia structures in human DLB and Alzheimer's (AD) post-mortem cases using the highly selective radioligand, [(3)H] GSK189254. In the main, the levels of H3 receptor were largely preserved in DLB cases when compared with aged-matched controls...
August 31, 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
Rajesh R Tampi, Deena J Tampi, Silpa Balachandran, Shilpa Srinivasan
BACKGROUND: The purpose of this review is to evaluate the data on the use of antipsychotics in individuals with dementia from meta-analyses. METHODS: We performed a literature search of PubMed, MEDLINE, EMBASE, PsycINFO and Cochrane collaboration databases through 30 November, 2015 using the following keywords: 'antipsychotics', 'dementia' and 'meta-analysis'. The search was not restricted by the age of the patients or the language of the study. However, in the final analysis we only included studies involving patients that were published in English language journals or had official English translations...
September 2016: Therapeutic Advances in Chronic Disease
Charisse Somers, Hanne Struyfs, Joery Goossens, Ellis Niemantsverdriet, Jill Luyckx, Naomi De Roeck, Ellen De Roeck, Bart De Vil, Patrick Cras, Jean-Jacques Martin, Peter-Paul De Deyn, Maria Bjerke, Sebastiaan Engelborghs
During the past ten years, over 5,000 cerebrospinal fluid (CSF) samples were analyzed at the Reference Center for Biological Markers of Dementia (BIODEM), UAntwerp, for core Alzheimer's disease (AD) CSF biomarkers: amyloid-β peptide of 42 amino acids (Aβ1-42), total tau protein (T-tau), and tau phosphorylated at threonine 181 (P-tau181P). CSF biomarker analyses were performed using single-analyte ELISA kits. In-house validated cutoff values were applied: Aβ1-42 <638.5 pg/mL, T-tau >296.5 pg/mL, P-tau181P >56...
August 10, 2016: Journal of Alzheimer's Disease: JAD
Samuel T Wilkinson, Rajiv Radhakrishnan, Deepak Cyril D'Souza
OBJECTIVE: Marijuana has been approved for a number of psychiatric conditions in many states in the US including posttraumatic stress disorder (PTSD), agitation in Alzheimer's disease, and Tourette's disorder. In this systematic review, we examine the strength of evidence for the efficacy of marijuana and other cannabinoids for these psychiatric indications. DATA SOURCES: The literature (MEDLINE) was searched for studies published between January 1980 and March 2015 using search terms related to marijuana and other cannabinoids and the specific diagnosis...
August 2016: Journal of Clinical Psychiatry
Ian McKeith, John-Paul Taylor, Alan Thomas, Paul Donaghy, Joseph Kane
Efforts to clinically diagnose cases having dementia with Lewy bodies (DLB) identify those with a characteristic clinical syndrome (probable DLB) at the expense of missing an equal, if not greater, number of cases who have atypical presentations thought to be associated with coexisting Alzheimer pathologies. This article argues that further efforts should now be made to characterize this atypical group that constitutes cases previously identified postmortem as the Lewy body variant of Alzheimer disease (AD) or as AD with Lewy bodies...
September 2016: Journal of Geriatric Psychiatry and Neurology
M Ferrari, C Comi, F Marino, L Magistrelli, F De Marchi, R Cantello, G Riboldazzi, G Bono, M Cosentino
BACKGROUND: Visual hallucinations (VHs) are frequent non-motor complication of Parkinson's disease (PD), associated to a negative prognosis. Previous studies showed an association between dopamine receptor (DR) gene (DR) variants and psychosis in Alzheimer's disease, addictions, schizophrenia, and bipolar disorder. However, there are only a few studies on DR variants and VHs in PD, which did not provide conclusive results. OBJECTIVES: The present study aimed to determine whether genetic differences of DR are associated with visual hallucinations (VHs) in a cohort of Parkinson's disease (PD) patients...
November 2016: European Journal of Clinical Pharmacology
Yaroslau Compta, Oscar Ramos-Campoy, Oriol Grau-Rivera, Martí Colom-Cadena, Jordi Clarimón, María José Martí, Ellen Gelpi
Progressive supranuclear palsy (PSP) is a low-prevalence atypical parkinsonism with underlying 4R-tauopathy and a growing number of clinical phenotypes, making its differential diagnosis from other conditions such as Parkinson's disease (PD) and corticobasal degeneration particularly challenging (1,2). Neuronal intermediate filament inclusion disease (NIFID), a sporadic alpha-internexin and fused-in-sarcoma (FUS) proteinopathy, is an even rarer condition with few cases published worldwide. It is most often diagnosed at autopsy, again due to a remarkable clinical heterogeneity ranging from young-onset frontotemporal dementia to PSP-lookalike parkinsonism, among other phenotypes (3-6)...
August 4, 2016: Neuropathology and Applied Neurobiology
Nikhil Bhagwat, Jon Pipitone, Julie L Winterburn, Ting Guo, Emma G Duerden, Aristotle N Voineskos, Martin Lepage, Steven P Miller, Jens C Pruessner, M Mallar Chakravarty
Recent advances in multi-atlas based algorithms address many of the previous limitations in model-based and probabilistic segmentation methods. However, at the label fusion stage, a majority of algorithms focus primarily on optimizing weight-maps associated with the atlas library based on a theoretical objective function that approximates the segmentation error. In contrast, we propose a novel method-Autocorrecting Walks over Localized Markov Random Fields (AWoL-MRF)-that aims at mimicking the sequential process of manual segmentation, which is the gold-standard for virtually all the segmentation methods...
2016: Frontiers in Neuroscience
M Bonafede, N Shi, R Barron, X Li, D B Crittenden, D Chandler
UNLABELLED: Patient characteristics contributing to imminent risk for fracture, defined as risk of near-term fracture within the next 12 to 24 months, have not been well defined. In patients without recent fracture, we identified factors predicting imminent risk for vertebral/nonvertebral fracture, including falls, age, comorbidities, and other potential fall risk factors. PURPOSE: Several factors contribute to long-term fracture risk in patients with osteoporosis, including age, bone mineral density, and fracture history...
December 2016: Archives of Osteoporosis
Ramón Cacabelos, Clara Torrellas, Lucía Fernández-Novoa, Francisco López-Muñoz
Neuroimmune dysregulation is a common phenomenon in different forms of central nervous system (CNS) disorders. Cross-links between central and peripheral immune mechanisms appear to be disrupted as reflected by a series of immune markers (CD3, CD4, CD7, HLA-DR, CD25, CD28, and CD56) which show variability in brain disorders such as anxiety, depression, psychosis, stroke, Alzheimer's disease, Parkinson's disease, attention-deficit hyperactivity disorder, migraine, epilepsy, vascular dementia, mental retardation, cerebrovascular encephalopathy, multiple sclerosis, brain tumors, cranial nerve neuropathies, mental retardation, and posttraumatic brain injury...
2016: Mediators of Inflammation
F Brossard, R Caron
OBJECTIVES: Various behavior disorders can occur during Alzheimer's disease, in particular unexpected outings. This article aims at understanding the diverse mechanisms present during a "runaway" episode, which can manifest in an acute way. The authors bring to light through clinical examples what is at work from a psychological perspective in order to create new accompaniment methods. METHOD: First, the authors reviewed the literature on runaway episodes in order to point out necessary themes for reflection...
May 11, 2016: L'Encéphale
Sheldon H Preskorn, Matthew Macaluso
This series of columns has 3 main goals: (1) to explain class warnings as used by the United States Food and Drug Administration, (2) to increase awareness of movement disorders that may occur in patients treated with antipsychotic medications, and (3) to understand why clinicians should refrain from immediately assuming a diagnosis of tardive dyskinesia/dystonia (TD) in patients who develop abnormal movements during treatment with antipsychotics. The first column in the series presented a patient who developed abnormal movements while being treated with aripiprazole as an augmentation strategy for major depressive disorder (MDD) and reviewed data concerning the historical background, incidence, prevalence, and risk factors for tardive and spontaneous dyskinesias, the clinical presentations of which closely resemble each other...
March 2016: Journal of Psychiatric Practice
Yaoming Zhai, Song Yin, Dongfeng Zhang
Antipsychotic drugs have been inconsistently associated with death risk of Alzheimer's disease (AD) patients. Herein we review and quantitatively summarize the evidence from epidemiological studies. Pertinent studies were identified by searching PubMed and Cochrane Library Register of Controlled Trials through 20 December 2015. The DerSimonian and Laird random effect model was adopted as the pooling method. Twelve studies from nine articles with 11,463 participants were included. The pooled RR of observational studies was 1...
March 31, 2016: Journal of Alzheimer's Disease: JAD
Young-Min Lee, Young-In Chung, Je-Min Park, Byung-Dae Lee, Eunsoo Moon, Hee-Jeong Jeong, Ji-Hoon Kim, Hak-Jin Kim, Chi-Woong Mun, Tae-Hyung Kim, Young-Hoon Kim, Eun-Joo Kim
The purpose of this study was to investigate the association between brain regional gray matter volume and two subtypes of psychotic symptoms, namely paranoid and misidentification subtypes, in antipsychotic-naïve mild or moderate Alzheimer's disease (AD) patients. Forty AD patients with psychotic symptoms and 25 AD patients without psychotic symptoms were assessed for cognitive and functional impairment. Presence and subtype of psychotic symptoms were assessed by using the delusion and hallucination subscale of the Korean Neuropsychiatric Inventory (K-NPI)...
March 30, 2016: Psychiatry Research
Jorge I Vélez, Dora Rivera, Claudio A Mastronardi, Hardip R Patel, Carlos Tobón, Andrés Villegas, Yeping Cai, Simon Easteal, Francisco Lopera, Mauricio Arcos-Burgos
We previously reported age of onset (AOO) modifier genes in the world's largest pedigree segregating early-onset Alzheimer's disease (AD), caused by the p.Glu280Ala (E280A) mutation in the PSEN1 gene. Here we report the results of a targeted analysis of functional exonic variants in those AOO modifier genes in sixty individuals with PSEN1 E280A AD who were whole-exome genotyped for ~250,000 variants. Standard quality control, filtering, and annotation for functional variants were applied, and common functional variants located in those previously reported as AOO modifier loci were selected...
2016: Neural Plasticity
Simon Kang Seng Ting, Ying Hao, Pei Shi Chia, Eng-King Tan, Shahul Hameed
Psychosis is common in Alzheimer's disease (AD). However, studies on neuropathology in vascular etiology contributing to psychosis in AD is lacking to date. The aim of this study was to investigate neuropathological vascular related changes in Alzheimer's disease with psychosis. Data of patients with AD from the National Alzheimer's Coordinating Center between 2005 to September 2013 was accessed and reviewed. Presence of psychosis was determined based on Neuropsychiatric Inventory Questionnaire taken from the last visit within one year prior to death, and patients were divided into psychosis positive and negative group...
2016: Scientific Reports
Young-Min Lee, Je-Min Park, Byung-Dae Lee, Eunsoo Moon, Hee-Jeong Jeong, Young-In Chung, Ji-Hoon Kim, Hak-Jin Kim, Chi-Woong Mun, Tae-Hyung Kim, Young-Hoon Kim
OBJECTIVE: The purpose of this study was to determine whether gray matter volumes are associated with treatment response of psychotic symptoms in Alzheimer's disease (AD) patients. METHOD: Risperidone, which is commonly used as an atypical antipsychotic drug, was administered in a clinical setting for 6 weeks from April 2012 to February 2013 to 25 antipsychotic-naïve AD patients with psychosis, diagnosed according to Jeste and Finkel's proposed diagnostic criteria for psychosis of Alzheimer's disease...
January 2016: Journal of Clinical Psychiatry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"